

# Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)\*

\*Developed with financial support from the Agency for Healthcare Research and Quality (AHRQ) and CMS under the CHIPRA Pediatric Quality Measures Program Centers of Excellence grant number U18HS025296.

---

## SUMMARY OF CHANGES TO HEDIS 2019

---

- Restructured the codes and value sets for identifying the required exclusions (step 4). Refer to the Value Set Directory for a detailed summary of changes.
- Clarified that schizoaffective disorder is included in step 4 of the event.
- Renamed the Other Psychotic Disorders Value Set to Other Psychotic and Developmental Disorders Value Set (codes remain unchanged).
- Removed acute inpatient encounter code combinations that referenced the Telehealth POS Value Set from step 4 (required exclusions).
- Removed “Lower 95% confidence interval” and “Upper 95% confidence interval” data elements from the Data Elements for Reporting tables.

## Description

The percentage of children and adolescents 1–17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.

## Definitions

|                                    |   |
|------------------------------------|---|
| <b>Intake Period</b>               | January 1 through December 1 of the measurement year.   |
| <b>IPSD</b>                        | Index Prescription Start Date. The earliest prescription dispensing date for an antipsychotic medication where the date is in the Intake Period and there is a Negative Medication History. |
| <b>Negative Medication History</b> | A period of 120 days (4 months) prior to the IPSD when the member had no antipsychotic medications dispensed for either new or refill prescriptions.  |

## Eligible Population

**Note:** *Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.*

|                      |   |
|----------------------|---|
| <b>Product lines</b> | Commercial, Medicaid (report each product line separately).   |
| <b>Ages</b>          | 1–17 years as of December 31 of the measurement year. Report three age stratifications and a total rate: <ul style="list-style-type: none"><li>• 1–5 years.</li><li>• 6–11 years.</li><li>• 12–17 years.</li><li>• Total.</li></ul> |

The total is the sum of the age stratifications.

|                                    |   |
|------------------------------------|---|
| <b>Continuous enrollment</b>       | 120 days (4 months) prior to the IPSD through 30 days after the IPSD.   |
| <b>Allowable gap</b>               | None.   |
| <b>Anchor date</b>                 | IPSD.   |
| <b>Benefit</b>                     | Medical, mental health, pharmacy.   |
| <b>Event</b>                       | Follow the steps below to identify the eligible population.   |
| <b>Step 1</b>                      | Identify all members in the specified age range who were dispensed an antipsychotic medication ( <u>Antipsychotic Medications List</u> ; <u>Antipsychotic Combination Medications List</u> ) during the Intake Period.  |
| <b>Step 2</b>                      | Test for Negative Medication History. For each member identified in step 1, test each antipsychotic prescription for a Negative Medication History. The IPSD is the dispensing date of the earliest antipsychotic prescription in the Intake Period with a Negative Medication History.   |
| <b>Step 3</b>                      | Calculate continuous enrollment. Members must be continuously enrolled for 120 days (4 months) prior to the IPSD through 30 days after the IPSD.  |
| <b>Step 4: Required exclusions</b> | <p>Exclude members for whom first-line antipsychotic medications may be clinically appropriate. Any of the following during the measurement year meet criteria:</p> <ul style="list-style-type: none"> <li>• At least one acute inpatient encounter with a diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, autism, or other developmental disorder during the measurement year. Any of the following code combinations meet criteria: <ul style="list-style-type: none"> <li>– <u>BH Stand Alone Acute Inpatient Value Set</u> with (<u>Schizophrenia Value Set</u>; <u>Bipolar Disorder Value Set</u>; <u>Other Psychotic and Developmental Disorders Value Set</u>).</li> <li>– <u>Visit Setting Unspecified Value Set</u> with <u>Acute Inpatient POS Value Set</u> with (<u>Schizophrenia Value Set</u>; <u>Bipolar Disorder Value Set</u>; <u>Other Psychotic and Developmental Disorders Value Set</u>), with or without a telehealth modifier (<u>Telehealth Modifier Value Set</u>).</li> </ul> </li> <li>• At least two visits in an outpatient, intensive outpatient or partial hospitalization setting, on different dates of service, with a diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, autism, or other developmental disorder during the measurement year. Any of the following code combinations with (<u>Schizophrenia Value Set</u>; <u>Bipolar Disorder Value Set</u>; <u>Other Psychotic and Developmental Disorders Value Set</u>), with or without a telehealth modifier (<u>Telehealth Modifier Value Set</u>), meet criteria: <ul style="list-style-type: none"> <li>– An outpatient visit (<u>Visit Setting Unspecified Value Set</u> with <u>Outpatient POS Value Set</u>).</li> <li>– An outpatient visit (<u>BH Outpatient Value Set</u>).</li> <li>– An intensive outpatient encounter or partial hospitalization (<u>Visit Setting Unspecified Value Set</u> with <u>Partial Hospitalization POS Value Set</u>).</li> <li>– An intensive outpatient encounter or partial hospitalization (<u>Partial Hospitalization/Intensive Outpatient Value Set</u>).</li> <li>– A community mental health center visit (<u>Visit Setting Unspecified Value Set</u> with <u>Community Mental Health Center POS Value Set</u>).</li> </ul> </li> </ul> |

- Electroconvulsive therapy (Electroconvulsive Therapy Value Set).
- An observation visit (Observation Value Set).
- A telehealth visit (Visit Setting Unspecified Value Set with Telehealth POS Value Set).

**Antipsychotic Medications**

| Description                        | Prescription   |  |   |
|------------------------------------|--|--|---|
| Miscellaneous antipsychotic agents | <ul style="list-style-type: none"> <li>• Aripiprazole</li> <li>• Asenapine</li> <li>• Brexpiprazole</li> <li>• Cariprazine</li> <li>• Clozapine</li> <li>• Haloperidol</li> <li>• Iloperidone</li> </ul> | <ul style="list-style-type: none"> <li>• Loxapine</li> <li>• Lurisdone</li> <li>• Molindone</li> <li>• Olanzapine</li> <li>• Paliperidone</li> <li>• Pimozide</li> <li>• Quetiapine</li> </ul> | <ul style="list-style-type: none"> <li>• Quetiapine fumarate</li> <li>• Risperidone</li> <li>• Ziprasidone</li> </ul> |
| Phenothiazine antipsychotics       | <ul style="list-style-type: none"> <li>• Chlorpromazine</li> <li>• Fluphenazine</li> <li>• Perphenazine</li> </ul>   | <ul style="list-style-type: none"> <li>• Prochlorperazine</li> <li>• Thioridazine</li> <li>• Trifluoperazine</li> </ul>  |   |
| Thioxanthenes                      | <ul style="list-style-type: none"> <li>• Thiothixene</li> </ul>  |  |   |
| Long-acting injections             | <ul style="list-style-type: none"> <li>• Aripiprazole</li> <li>• Fluphenazine decanoate</li> <li>• Haloperidol decanoate</li> </ul>  | <ul style="list-style-type: none"> <li>• Olanzapine</li> <li>• Paliperidone palmitate</li> </ul>   | <ul style="list-style-type: none"> <li>• Risperidone</li> </ul>   |

**Antipsychotic Combination Medications**

| Description                    | Prescription  |  |
|--------------------------------|---|--|
| Psychotherapeutic combinations | <ul style="list-style-type: none"> <li>• Fluoxetine-olanzapine</li> </ul> | <ul style="list-style-type: none"> <li>• Perphenazine-amitriptyline</li> </ul> |

**Administrative Specification**

- Denominator** The eligible population.
- Numerator** Documentation of psychosocial care (Psychosocial Care Value Set) with or without a telehealth modifier (Telehealth Modifier Value Set) in the 121-day period from 90 days prior to the IPSD through 30 days after the IPSD.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table APP-1/2: Data Elements Access to Psychosocial Care for Children and Adolescents on Antipsychotics**

|  | Administrative                               |
|--|--|
| Measurement year                             | ✓  |
| Data collection methodology (Administrative) | ✓  |
| Eligible population                          | <i>For each age stratification and total</i> |
| Number of required exclusions                | <i>For each age stratification and total</i> |
| Numerator events by administrative data      | <i>For each age stratification and total</i> |
| Reported rate                                | <i>For each age stratification and total</i> |